Catheterization and Cardiovascular Interventions

Vascular closure after transfemoral transcatheter aortic valve replacement: Further randomized trials are justified. 2023

Drug-coated balloon treatment of complex femoropopliteal disease yields favorable and durable outcomes at 5 years.  100:1284-1285. 2022

Percutaneous coronary intervention in the polyvascular patient remains a high-risk procedure.  100:747-748. 2022

Ticagrelor monotherapy after coronary stenting in patients requiring proton pump inhibitor and prolonged antiplatelet therapy.  100:83-84. 2022

Successfully treating the common femoral artery “no go zone” with directional atherectomy plus antirestenotic therapy (DAART).  99:1317-1318. 2022

Safety of the transradial approach to carotid stenting.  99:814-821. 2022

Covered stents favored in complex aortoiliac disease.  98:938-939. 2021

Diabetes and everolimus eluting bioresorbable poly-L-lactide vascular scaffolds for coronary artery disease: Dead-end or some path forward?.  98:721-722. 2021

Critical limb ischemia in the end stage renal disease patient: Some next steps.  98:308-309. 2021

Genotype-guided antiplatelet therapy for acute coronary syndrome percutaneous coronary intervention patients: A new standard of care?.  97:795-796. 2021

Antiplatelet therapy regimen and duration after percutaneous coronary intervention: Combining prediction scores with clinical judgment.  97:579-580. 2021

A new intravascular ultrasound-guided stenting strategy compared with angiography on stent expansion and procedural outcomes in patients with positive lesion remodeling.  97:237-244. 2021

Everolimus eluting bioresorbable vascular scaffolds for infrapopliteal critical limb ischemia: Moving beyond grasping at metal straws.  97:150-151. 2021

Ticagrelor monotherapy: When is mono-antiplatelet therapy (MAPT) equivalent or better?.  96:1379-1380. 2020

Codeployment of a percutaneous edge-to-edge mitral valve repair device and a ventriculoseptal defect occluder device to address complex mitral regurgitation with leaflet perforation.  96:1333-1338. 2020

Radial access and risk guided use of bivalirudin?.  96:1249-1250. 2020

Safety and efficacy of paclitaxel drug-coated balloon treatment of femoropopliteal claudicants: Data and analytic methods matter.  96:1100-1101. 2020

A step toward physiologically guided chronic limb-threatening ischemia intervention.  96:913-914. 2020

Insulin-treated diabetes mellitus: An actionable risk factor and marker after percutaneous coronary intervention.  96:309-310. 2020

A step forward in predicting anterograde crossing success for infrapopliteal chronic total occlusions.  95:756-757. 2020

Prior probability of significant obstructive arterial disease in the contralateral lower extremity.  95:307-308. 2020

Clopidogrel pretreatment may reduce early acquired thrombocytopenia after transcatheter aortic valve replacement (TAVR).  94:818-819. 2019

Costs of postoperative delirium with transcatheter aortic valve replacement: Improved yet still present.  93:1137. 2019

Intravascular ultrasound of normal left main arteries: Insights for stent optimization and standardization.  93:239-240. 2019

Embolic stroke of undetermined source and patent foramen ovale closure: Practice insights from meta-analysis?.  92:1161-1162. 2018

Anchor balloon, buddy wire, and wire and sheath techniques to deploy percutaneous pulmonary valves in tetralogy of fallot patients.  92:915-920. 2018

“Expanding the frame” for valve-in-valve therapy in small bioprostheses: Encouraging signs for the road ahead.  92:555-556. 2018

Surgical aortic valve replacement and transcatheter aortic valve implantation for severe aortic stenosis: Equipoise remains a tenable assumption.  92:431-432. 2018

Patent foramen ovale closure for cryptogenic stroke: Effective, but only in select patients.  92:174-175. 2018

Long-term survival prospects of patients undergoing percutaneous coronary intervention: Envisioning the future.  91:696. 2018

The promise of effective P2Y12 platelet receptor pretreatment: Not crushed yet.  91:251-252. 2018

Patient preference: An important emerging factor in operator access site selection.  91:25-26. 2018

Individualizing dual antiplatelet therapy duration: Prediction tools, genomics, and clinical judgment.  90:38. 2017

Length and pressure matter: Expediting evidence-based progress in femoropoliteal intervention.  89:1257-1258. 2017

The many radial access learning curves.  89:865-866. 2017

Utility of the HAS-BLED Score in Risk Stratifying Patients on Dual Antiplatelet Therapy Post 12 Months After Drug-Eluting Stent Placement.  89:E99-E103. 2017

Unprotected Left Main Disease and Percutaneous Intervention: A Prototype for Precision Medicine.  89:11-12. 2017

Radial Access Optimization in the Nascent Post-Adoption Era.  88:1044-1045. 2016

Routine invasive evaluation in non ST elevation myocardial infarction (NSTEMI-ACS): Optimizing best.  88:775-776. 2016

End of the bare metal stent era?.  88:49-50. 2016

Emergent transcatheter mitral valve-in-valve implantation in a patient with cardiogenic shock secondary to a failed mitral bioprosthesis.  87:1342-1346. 2016

Simultaneous transcatheter pulmonary and tricuspid valve-in-valve implantation for the treatment of failing pulmonary and tricuspid bioprostheses.  87:1352-1355. 2016

Risk-guided use of the direct thrombin inhibitor bivalirudin.  87:401-402. 2016

Insulin-treated diabetes mellitus: An important, actionable risk marker after coronary stenting.  87:63-64. 2016

Diabetes is not sufficient justification for IIb/IIIa use in percutaneous coronary intervention.  86:376-377. 2015

Renal artery stenting: Patient selection post-CORAL.  86:310-311. 2015

Obesity and percutaneous coronary intervention outcomes: Beware the extremes.  85:959-960. 2015

Percutaneous coronary intervention: Ever closer to real world silver bullets!?.  85:807-808. 2015

Can femoral access bleeding outcomes be improved?.  85:380-381. 2015

Optimal DAPT duration: Each in their own time.  85:41-42. 2015

Shorter (≤ 6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: A meta-analysis of randomized clinical trials.  85:34-40. 2015

Outcomes of carotid stenting in patients with previous neck radiation.  82:689-695. 2013

Thromboaspiration and IIb/IIIa therapy in STEMI: Abciximab redux?.  82:612-613. 2013

Stent paleology: Diabetic lessons from extinct stents.  81:1125-1126. 2013

Diabetes and everolimus-eluting stents: Good offense scores but defense wins tough games.  81:766-767. 2013

Embozene™ microspheres induced nonreperfused myocardial infarction in an experimental swine model.  81:689-697. 2013

Saphenous vein grafts: Two substrates, two treatments?.  80:1137. 2012

Benefit of renal artery stenting: Is on-target therapy the observational bias?.  80:351. 2012

Rotational atherectomy for heavily calcified unprotected left main disease: Proceed with caution.  80:221. 2012

Implicit rationing of percutaneous coronary intervention: The left main test case.  79:1117. 2012

Diabetes and percutaneous coronary intervention drug-eluting: Stents whenever feasible.  78:718-719. 2011

Quality assessment and improvement in interventional cardiology: A position statement of the society of cardiovascular angiography and interventions, Part II: Public reporting and risk adjustment.  78:493-502. 2011

Shock and age: The role of an early invasive strategy.  78:512-513. 2011

A novel clinical prediction rule for 30-day mortality following balloon aortic valuloplasty: The CRRAC the AV score.  78:112-118. 2011

Quality assessment and improvement in interventional cardiology: A position statement of the Society of Cardiovascular Angiography and Interventions, part 1: Standards for quality assessment and improvement in interventional cardiology.  77:927-935. 2011

A full toolbox fixes the roadblocks.  77:759-760. 2011

DES in SVGs: Safe and at least short-term effective.  77:356-357. 2011

The outcome of pulmonary artery stents following surgical manipulation.  77:390-394. 2011

High glycemic stenting menu.  76:934-935. 2010

Drug-eluting or bare metal stents for diabetics: Clinical judgment still wins.  76:482-483. 2010

The holy grail for DES: Does efficacy translate into real world effectiveness?.  76:381-382. 2010

Which DES for diabetics? Round 1: A draw. Round 2: Everolimus leading?.  76:58-59. 2010

Pulmonary artery stents: Long-term follow-up.  75:757-764. 2010

Bifurcation stenting: A commitment to always kiss.  75:614-615. 2010

As goes the access, so goes the intervention?.  74:932-933. 2009

The modern axis of peri-procedural evil.  74:56-57. 2009

Multivessel disease in diabetics: Does DES level the field?.  73:881-882. 2009

A third dimension to uncloud the funnel plot of operator quality.  73:595-596. 2009

Long-term follow-up of the STARFlex® device for closure of secundum atrial septal defect.  73:190-195. 2009

Length matters: outcomes of superficial femoral artery (SFA) endovascular interventions..  74:1096. 2009

Stent fractures in congenital heart disease.  72:977-982. 2008

Native vessel PCI in the diabetic: DES whenever feasible.  72:608-609. 2008

Hemodynamic evaluation of coronary artery bypass graft lesions using fractional flow reserve.  72:479-485. 2008

Time is muscle; but should it be D2B or D2T?.  72:424-425. 2008

The bone marrow and endovascular therapy.  72:210-211. 2008

DES in saphenous bypass grafts: A treatment in vain?.  72:21-22. 2008

Feasibility of primary clot extraction prior to percutaneous coronary intervention in acute myocardial infarction.  71:870-876. 2008

Origin of all three major coronary arteries from the right sinus of valsalva: Clinical, angiographic, and magnetic resonance imaging findings and incidence in a select referral population.  69:711-718. 2007

B-type natriuretic peptide level in a patient with constrictive pericarditis..  68:832-834. 2006

Fatal subclavian stent infection remote from implantation.  65:535-539. 2005

Cypher drug-eluting stent treatment of tibioperoneal obstructive disease: A case report.  64:237-241. 2005

Carotid stenting for symptomatic radiation-induced arteritis complicated by recurrent aneurysm formation.  63:507-511. 2004

Long-Term Follow-Up of Brachytherapy for Treatment of Allograft In-Stent Restenosis.  61:217-221. 2004

High-output congestive heart failure successfully treated with transcatheter coil embolization of a large renal arteriovenous fistula.  63:373-376. 2004

Thermography basket catheter: In vivo measurement of the temperature of atherosclerotic plaques for detection of vulnerable plaques.  59:52-59. 2003

How to define coronary stenosis severity?.  53:202-203. 2001

Acute alveolar hemorrhage and orthodeoxia induced by intravenous amiodarone..  47:61-63. 1999

Stent procedure complicated by thrombus formation distal to the lesion within a muscle bridge.  43:73-76. 1998

Closure of an iatrogenic femoral artery pseudoaneurysm by transcutaneous coil embolization..  39:317-319. 1996

Slow coronary flow: Clinical and histopathological features in patients with otherwise normal epicardial coronary arteries.  37:375-381. 1996

Vegetation biopsy using transesophageal echocardiography guidance: A technique to aid in diagnosis of culture-negative endocarditis.  37:215-217. 1996

Aortic counterpulsation: Small and large balloons.  36:88-89. 1995

Intravascular ultrasound in the management of acute coronary artery dissection: A case report.  34:251-254. 1995

Sudden cardiac death from coronary artery spasm in a healthy subject.  32:171-173. 1994

Selective injection of a left coronary artery arising anomalously from the posterior aortic sinus.  30:300-302. 1993

Simplified method for calculating aortic valve resistance: Correlation with valve area and standard formula.  30:15-21. 1993

The perfusion pattern in coronary artery occlusion: Comparison of exercise and adenosine.  27:255-258. 1992

Systemic heparinization does not prevent clot formation in coil embolization.  20:267-270. 1990

Cardiac catheterization: Who's doing the teaching?.  16:147-148. 1989

Dual connection of the left anterior descending coronary artery to the left and right coronary arteries.  16:168-172. 1989

Myocardial ischemia during pharmacologic coronary vasodilatation: A concept in search of definition.  18:65-66. 1989

Practical considerations in pericardiocentesis.  16:24-24. 1989

Sarcoidosis, pulmonary hypertension, and acquired peripheral pulmonary artery stenosis.  11:69-74. 1985

Hemodynamic profile of constrictive pericarditis produced by a massive right pleural effusion.  10:471-477. 1984

Myocardial perforation due to temporary transvenous pacing catheters in pediatric patients.  10:329-333. 1984

Echocardiographic definition of right pulmonary venous connection at catheterization.  9:519-525. 1983

Aneurysm of a saphenous vein bypass graft associated with aneurysms of native coronary arteries.  8:489-494. 1982

Significance of collateral circulation in patients with left main coronary artery disease.  4:135-141. 1978

Comparison of Indices of Muscle and Pump Performance in Patients with Coronary Artery Disease.  1:17-34. 1975